Force Protection shares rise on fourth-quarter results
(10:10 AM ET) SAN FRANCISCO (MarketWatch) -- Force Protection Inc. /zigman2/quotes/204676095/composite FRPT +4.62% shares rose 8% to $17.26 in Monday morning trade. Late Friday, the Ladson, S.C.-based maker of protective vehicles reported fourth-quarter net earnings of $17 million, or 39 cents a share, on revenue of $62.9 million.
Movie Gallery loss narrows
(7:51 AM ET) NEW YORK (MarketWatch) - Video-rental company Movie Gallery Inc.said Monday its fourth-quarter net loss narrowed to $15.1 million, or 47 cents a share, from a loss of $546.5 million, or $17.25 a share. Total revenue fell to $663.3 million from $676.4 million. Rental revenue fell to $490.5 million from $520.4 million, while product sales rose to $172.8 million from about $156 million. Same-store total revenues for the fourth quarter decreased 2.9%, as same-store revenue slipped 0.3% at Movie Gallery branded stores and fell 4.1% at Hollywood branded stores.
Wolseley profit falls 14.7% on U.S. market weakness
(3:33 AM ET) LONDON (MarketWatch) -- U.K. construction materials group Wolseley Plcsaid Monday that its net profit for the six months ended Jan. 31 fell 14.7% to 209 million pounds ($406 million). Revenue for the period rose 23.7% to 7.87 billion pounds. The company said the drop in profit was mainly due to weakness in the North American housing market, a fall in prices and the result of exchange rate changes. Revenue growth mainly came from Europe due to the acquisition of DT Group and double-digit organic growth. Wolseley said the U.S. housing market is expected to remain soft for the rest of the calendar year, though the home repairs and commercial and industrial markets are expected to hold up. Wolseley also said it expects will see greater benefits from its cost reduction program in the second half of the year.
France's Ipsen '06 profit off 3%, revenue up 6.5%
(2:55 AM ET) TEL AVIV (MarketWatch) -- Ipsen, /zigman2/quotes/200122335/delayed FR:IPN -1.47% the Paris developer of therapies for oncology, endocrinology and neuromuscular disorders, reported 2006 profit fell 3% on 6.5% higher revenue. Earnings were 144 million euros ($191.6 milion), or 1.71 euros a share, against 148.6 million, or 2.2, in the year-earlier period. Shares outstanding rose 25% to 84 million. On a recurring operating basis, earnings rose 16% to 148.9 million euros. Total revenue rose 6.5% to 945.3 million euros, while sales were 6.8% higher at 861.7 million. For 2007, the company targets revenue growth of 4% to 5% and an operating-profit margin of 22% to 23% of sales. The company said it has five filings for products under review by regulators.